Wird geladen...
Practical management of patients with myelofibrosis receiving ruxolitinib
Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, IN...
Gespeichert in:
| Veröffentlicht in: | Expert Rev Hematol |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2013
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8201600/ https://ncbi.nlm.nih.gov/pubmed/24083419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/17474086.2013.827413 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|